Bone Biologics Corp (BBLG) is identified as the issuer in a Form 25 notification filed by Nasdaq Stock Market LLC concerning removal of the company’s warrant class from listing and/or registration on Nasdaq under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states that it has reasonable grounds to believe it meets the requirements for filing the notification.
Bone Biologics Corp director Robert E. Gagnon was granted non-employee stock options covering 113,896 Common Stock shares on September 28, 2026, at an exercise price of $0.50 per share. The report also lists directly held options for 10,483 shares at $5.28, 5,119 at $10.38, 2 at $25.44, and 1,335 at $25.44; these existing options are fully exercisable.
Bone Biologics Corp director Siddhesh Rajendra Angle received a grant of 113,896 non-employee stock options on September 28, 2026. The options have a $0.50 exercise price and expire September 28, 2036. The award was made under Bone Biologics Corporation's 2015 Equity Incentive Plan and described as exempt under Rule 16b-3.
Bone Biologics Corp director Phillip Terry Meikle II received non-employee stock options covering 113,896 common shares on September 28, 2026. They have a $0.50 exercise price, expire September 28, 2036, and generally vest in four equal quarterly installments, except as otherwise provided in the award notice. Other listed options cover 10,483 shares at $5.28, expiring June 4, 2035, and separate positions covering 4,698 and 2 shares at $11.28, expiring October 16, 2034; those options are fully exercisable as of the report date.
Bone Biologics Corp director Bruce Stroever received a grant of 113,896 non-employee stock options on September 28, 2026, with an exercise price of $0.50 per share and expiration on September 28, 2036. A separate direct option position covers 10,483 underlying shares at $5.28 per share and expires June 4, 2035.
Bone Biologics Corp. (BBLG) reported that shareholders at its September 28, 2026 annual meeting elected Bruce Stroever, Siddhesh Angle, Robert Gagnon and Philip Meikle as directors to serve until the next annual meeting and until their successors are duly elected and qualified. Shareholders also approved executive compensation on an advisory basis and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders approved the potential issuance of shares underlying certain warrants in an amount equal to or exceeding 20% of common stock outstanding immediately before the warrants were issued. They also approved an amendment authorizing a reverse stock split from 1-for-2 to 1-for-10, at the board’s discretion. The adjournment proposal passed, but an adjournment was unnecessary because Proposals 1–5 passed. Of 2,011,057 shares entitled to vote, 951,746 were present or represented by proxy.
Bone Biologics Corp (BBLG) reports a Nasdaq bid‑price deficiency notice after its common stock closed below $1 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until March 9, 2027, to regain compliance by achieving a closing bid of at least $1 per share for a minimum of 10 consecutive business days.
If compliance is not regained by March 9, 2027, the company may qualify for a second 180‑day period if it meets certain other Nasdaq Capital Market standards and notifies Nasdaq of its intent to cure the deficiency. Failure to comply could lead to delisting, subject to an appeal. The company states it will monitor its share price and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting, which its board may use to attempt to increase the share price and restore compliance. The notice has no immediate effect on the current Nasdaq listing.
Bone Biologics Corporation (BBLG) is asking stockholders at the September 28, 2026 annual meeting to elect four directors, approve executive compensation on an advisory basis, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
The company also seeks approval under Nasdaq Listing Rule 5635(d) for the potential issuance of up to 4,352,115 shares of common stock underlying warrants issued in a July 7, 2026 private placement and to the placement agent. As of August 6, 2026, common shares outstanding were 2,011,057. The private placement provided approximately $2.7 million of net proceeds, with up to approximately $6.0 million of additional gross proceeds possible if the Common Warrants are fully exercised for cash.
Stockholders are further asked to authorize a reverse stock split of the common stock within a range of 1‑for‑2 to 1‑for‑10, at the Board’s discretion and without reducing the 100,000,000 authorized shares, and to approve potential adjournment of the meeting if needed to secure sufficient votes or a quorum.
Bone Biologics Corporation reported no revenue and a net loss of $1.54 million for the six months ended June 30 2026, an improvement from a $1.76 million loss a year earlier as total operating expenses declined 9.7% to $1.61 million. Research and development spending fell 26.8% to $450,344, largely due to timing of clinical trial activities, while general and administrative costs were roughly flat.
Cash totaled $4.03 million at June 30 2026, down from $5.33 million at year-end, with $1.32 million used in operating activities in the first half. Subsequent to quarter-end, the company completed a July 2026 private placement of pre-funded and common stock warrants, generating approximately $2.7 million in net proceeds and extending expected funding into the second quarter of 2027.
Management and the auditors state that recurring losses, an accumulated deficit of about $89.7 million, and limited capital resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing. The company remains a clinical-stage medical device business focused on its NELL-1/DBM spinal fusion program, with ongoing pilot clinical work in Australia and significant future spending anticipated to support pivotal trials and regulatory approval.
Bone Biologics Corporation provided a mid-2026 shareholder update covering financing, clinical progress and manufacturing readiness for NB1, its rhNELL-1-based bone graft candidate for spinal fusion. In July 2026, the company completed a private placement with a single healthcare-focused institutional investor, generating approximately $3.0 million in gross proceeds before fees.
The financing included Series F and Series G warrants that could deliver up to approximately $6.0 million in additional gross proceeds if fully exercised for cash. Bone Biologics believes this capital extends its operating runway through Q2 2027 to support clinical trials, patent portfolio work and general operations. The company continues its first-in-human NB1 pilot study and expects to complete enrollment by year-end 2026. In May 2026, the validated shelf life of the rhNELL-1 protein was extended to 29 months, supporting manufacturing and supply-chain planning.